

ASX Release

Non Executive Director Resignation

BRISBANE & MELBOURNE, 28th September 2018: Anataro Lifesciences (ASX:ANR) advises that Mr Iain Ross has resigned as Non-Executive Director for personal reasons, effective as at 30th September 2018.

Anataro's Chair, Sue MacLeman said, "Iain has made a significant contribution to Anataro's board since his appointment as a Non-Executive Director in 2013, soon after the Company's inception and prior to the ASX listing. His experience and insights will be greatly missed. The Board respects Iain's request to step down immediately and wishes him well."

Mr Ross said "For personal reasons, I have no other choice but to stand down as an Anataro Board member and I wish the Board and Management all their very best in their future endeavours."

The Board intends to recruit a Non-Executive Director with experience in the area of human health.

For more information please contact:

Investor inquiries	Media inquiries
Sue MacLeman Chair Anataro Lifesciences +61 (0) 437 211 200 smacleman@anataro.com	Jane Lowe Managing Director IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anataro Lifesciences

Anataro Lifesciences (ASX: ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anataro granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anataro is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anatarolifesciences.com.